Phase II single arm study of durvalumab and olaparib (D plus O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)

被引：0
|
作者：
Fujii, T. [1 ]
Lipkowitz, S. [1 ]
Zimmer, A. D. S. [1 ]
Villanueva, E. [1 ]
Solarz, B. B. [1 ]
Lee, J-M. [1 ]
机构：
[1] Natl Canc Insitute, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.611
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
435P
引用
收藏
页码：S364 / S364
页数：1
相关论文
共 50 条
  • [1] A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
    Mitri, Zahi Ibrahim
    Vuky, Jacqueline
    Kemmer, Kathleen A.
    Savin, Michael A.
    Parmar, Swapnil
    Kolodzie, Annette Kolodzie
    Johnson, Brett
    Williams-Belizaire, Rochelle
    Gray, Joe W.
    Mills, Gordon B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S.
    Postel-Vinay, S.
    Im, S-A.
    Park, Y. H.
    Delord, J-P.
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Wang, D.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Lai, Z.
    Gresty, C.
    Opincar, L. M.
    Herbolsheimer, P.
    Kaufman, B.
    ANNALS OF ONCOLOGY, 2019, 30 : 477 - 477
  • [3] Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
    Tan, Tira J.
    Sammons, Sarah
    Im, Young-Hyuck
    She, Lilin
    Mundy, Kelly
    Bigelow, Robert
    Traina, Tiffany A.
    Anders, Carey
    Yeong, Joe
    Renzulli, Ezequiel
    Kim, Sung-Bae
    Dent, Rebecca
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1240 - 1247
  • [4] Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations
    Hong, Sanghee
    Funchain, Pauline
    Haddad, Abdo
    Crowe, Joseph
    Dalpiaz, Nancy
    Abraham, Jame
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (03) : 270 - +
  • [5] A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC).
    Tolaney, Sara M.
    Ziehr, David R.
    Guo, Hao
    Barry, William Thomas
    Higgins, Michaela Jane
    Isakoff, Steven J.
    Brock, Jane E.
    Ivanova, Elena
    Paweletz, Cloud
    Demeo, Michelle
    Ramaiya, Nikhil H.
    Overmoyer, Beth
    Jain, Rakesh K.
    Duda, Dan G.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
    Domchek, Susan M.
    Postel-Vinay, Sophie
    Bang, Yung-Jue
    Park, Yeonh H.
    Alexandre, Jerome
    Delord, Jean-Pierre
    Italiano, Antoine
    You, Benoit
    Bastian, Sara
    Krebs, Matthew
    Wang, Ding
    Waqar, Saiama
    Angell, Helen
    Learoyd, Maria
    Chang, Shao-Chun
    Gresty, Christopher
    Herbolsheimer, Pia
    Kaufman, Bella
    CANCER RESEARCH, 2018, 78 (04)
  • [7] Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
    Pohl, E.
    Schneeweiss, A.
    Hauke, J.
    Moebus, V.
    Furlanetto, J.
    Denkert, C.
    Fasching, P. A.
    Hanusch, C.
    Tesch, H.
    Weber-Lassalle, N.
    Mueller, V.
    Rhiem, K.
    Untch, M.
    Luebbe, K.
    Lederer, B.
    Jackisch, C.
    Nekljudova, V.
    Schmutzler, R. K.
    Hahnen, E.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
    Domchek, S. M.
    Postel-Vinay, S.
    Im, S-A
    Park, Y. Hee
    Delord, J-P
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Tang, M.
    Gresty, C.
    Opincar, L.
    Herbolsheimer, P.
    Kaufman, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).
    Sammons, Sarah
    Tira Jing Ying Tan
    Traina, Tiffany A.
    Kim, Sung-Bae
    Im, Young-Hyuck
    Bachelder, Carol
    Marcom, Paul Kelly
    Dent, Rebecca Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study
    Recchia, Francesco
    Candeloro, Giampiero
    Desideri, Giovambattista
    Necozione, Stefano
    Recchia, Cornelia O. C.
    Cirulli, Vincenzo
    Rea, Silvio
    CANCER MEDICINE, 2012, 1 (01): : 89 - 95
12345